{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:48:11Z","timestamp":1762102091192,"version":"3.41.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["219707"],"award-info":[{"award-number":["219707"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Netherlands Organization for Scientific Research","award":["VIDI 917.11.349"],"award-info":[{"award-number":["VIDI 917.11.349"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s10194-017-0812-4","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T12:10:33Z","timestamp":1507723833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of \u03b11- and \u03b12-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats"],"prefix":"10.1186","volume":"18","author":[{"given":"Eduardo","family":"Rivera-Mancilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor H.","family":"Avil\u00e9s-Rosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Manrique-Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain H.","family":"Altamirano-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Villanueva-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-1343","authenticated-orcid":false,"given":"Carlos M.","family":"Villal\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"812_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","volume":"43","author":"SD Silberstein","year":"2003","unstructured":"Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43:144\u2013166","journal-title":"Headache"},{"key":"812_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1570161033386826","volume":"1","author":"CM Villal\u00f3n","year":"2003","unstructured":"Villal\u00f3n CM, Centuri\u00f3n D, Valdivia LF et al (2003) Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1:71\u201384","journal-title":"Curr Vasc Pharmacol"},{"key":"812_CR3","first-page":"43","volume":"2","author":"J Stewart","year":"2013","unstructured":"Stewart J, Tepper MD (2013) Orally inhaled dihydroergotamine: a review. Headache 2:43\u201353","journal-title":"Headache"},{"key":"812_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/head.12269","volume":"54","author":"P Tfelt-Hansen","year":"2014","unstructured":"Tfelt-Hansen P (2014) Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE? Headache 54:383","journal-title":"Headache"},{"key":"812_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-013-0061-2","volume":"27","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Kori SH (2013) Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs 27:385\u2013394","journal-title":"CNS Drugs"},{"key":"812_CR6","first-page":"30","volume":"284","author":"J Roquebert","year":"1986","unstructured":"Roquebert J, Greni\u00e9 B (1986) \u03b12-adrenergic agonist and \u03b11-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn 284:30\u201337","journal-title":"Arch Int Pharmacodyn"},{"key":"812_CR7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0026-895X(25)09616-6","volume":"50","author":"JE Leysen","year":"1996","unstructured":"Leysen JE, Gommeren W, Heylen L et al (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hidroxytryptamine1D\u03b1, human 5-hidroxytryptamine1D\u03b2, and calf 5-hidroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 50:1567\u20131580","journal-title":"Mol Pharmacol"},{"key":"812_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00210-007-0179-1","volume":"376","author":"CM Villal\u00f3n","year":"2007","unstructured":"Villal\u00f3n CM, Centuri\u00f3n D (2007) Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors\/mechanisms involved and therapeutic implications. Naunyn Schmiedeberg's Arch Pharmacol 376:45\u201363","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"812_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X","volume":"35","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Newman-Tancredi A, Auinot V et al (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79\u201395","journal-title":"Synapse"},{"key":"812_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ejphar.2013.05.011","volume":"715","author":"MT Villamil-Hern\u00e1ndez","year":"2013","unstructured":"Villamil-Hern\u00e1ndez MT, Alc\u00e1ntara-V\u00e1zquez O, S\u00e1nchez-L\u00f3pez A et al (2013) Pharmacological identification of \u03b11- and \u03b12-adrenoceptor subtypes involved in the vasopresor responses induced by ergotamine in pithed rats. Eur J Pharmacol 715:262\u2013269","journal-title":"Eur J Pharmacol"},{"key":"812_CR11","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.lfs.2003.10.033","volume":"74","author":"LF Valdivia","year":"2004","unstructured":"Valdivia LF, Centuri\u00f3n D, Perusqu\u00eda M et al (2004) Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats. Life Sci 74:3223\u20133234","journal-title":"Life Sci"},{"key":"812_CR12","doi-asserted-by":"crossref","unstructured":"Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E, Hern\u00e1ndez-Abreu O et al (2017) Pharmacological analysis of the increases in heart rate and diastolic blood pressure produced by (S)-isometheptene and (R)-isometheptene in pithed rats. J Headache Pain 18:52","DOI":"10.1186\/s10194-017-0761-y"},{"key":"812_CR13","doi-asserted-by":"crossref","unstructured":"Villamil-Hern\u00e1ndez MT, Alc\u00e1ntara-V\u00e1zquez O, S\u00e1nchez-L\u00f3pez A et al (2012) Pharmacological identification of the \u03b12-adrenoceptor subtypes mediating the vasopressor responses to B-HT 933 in pithed rats. Eur J Pharmacol 691:118\u2013124","DOI":"10.1016\/j.ejphar.2012.06.011"},{"key":"812_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1476-5381.1995.tb14977.x","volume":"115","author":"DW Bonhaus","year":"1995","unstructured":"Bonhaus DW, Bach C, DeSouza A et al (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115:622\u2013628","journal-title":"Br J Pharmacol"},{"key":"812_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejphar.2006.02.010","volume":"535","author":"D Centuri\u00f3n","year":"2006","unstructured":"Centuri\u00f3n D, S\u00e1nchez-L\u00f3pez A, Gupta S et al (2006) Potential vascular \u03b11-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. Eur J Pharmacol 535:234\u2013242","journal-title":"Eur J Pharmacol"},{"key":"812_CR16","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/sj.bjp.0704593","volume":"135","author":"D Centuri\u00f3n","year":"2002","unstructured":"Centuri\u00f3n D, Ortiz MI, Saxena PR et al (2002) The atypical 5-HT2 receptors mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype. Br J Pharmacol 135:1531\u20131539","journal-title":"Br J Pharmacol"},{"key":"812_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/bph.12358","volume":"170","author":"AH Altamirano-Espinoza","year":"2013","unstructured":"Altamirano-Espinoza AH, Gonz\u00e1lez-Hern\u00e1ndez A, Manrique-Maldonado G et al (2013) The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Br J Pharmacol 170:1102\u20131111","journal-title":"Br J Pharmacol"},{"key":"812_CR18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1152\/jappl.1964.19.2.360","volume":"19","author":"LI Kleinman","year":"1964","unstructured":"Kleinman LI, Radford EP (1964) Ventilation standards for small mammals. J Appl Physiol 19:360\u2013362","journal-title":"J Appl Physiol"},{"key":"812_CR19","doi-asserted-by":"crossref","unstructured":"Curtis MJ, Bond RA, Spina D et al (2015) Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172:3461\u20133471","DOI":"10.1111\/bph.12856"},{"key":"812_CR20","volume-title":"Principles and Procedures of Statistics: a Biomedical Approach","author":"RGD Steel","year":"1980","unstructured":"Steel RGD, Torrie JH (1980) Principles and Procedures of Statistics: a Biomedical Approach, 2nd edn. Tokyo, McGraw-Hill, Kogakusha Ltd","edition":"2"},{"key":"812_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0306-3623(94)90104-X","volume":"25","author":"S Kaneta","year":"1994","unstructured":"Kaneta S, Kashiwabara T, Tanaka Y et al (1994) Cardiovascular effects of KRN2391, nitroglycerin and cromakalim in dihydroergotamine-treated pithed rats. Gen Pharmacol 25:963\u2013968","journal-title":"Gen Pharmacol"},{"key":"812_CR22","first-page":"43","volume-title":"Serotonin and the cardiovascular system","author":"JE Leysen","year":"1985","unstructured":"Leysen JE (1985) Serotonergic binding sites. In: Vanhoutte PM (ed) Serotonin and the cardiovascular system. Raven Press, New York, pp 43\u201362"},{"key":"812_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/BF00541928","volume":"26","author":"E M\u00fcller-Schweinitzer","year":"1984","unstructured":"M\u00fcller-Schweinitzer E (1984) Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 26:699\u2013705","journal-title":"Eur J Clin Pharmacol"},{"key":"812_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.CIR.98.1.25","volume":"98","author":"A MaassenVanDenBrink","year":"1998","unstructured":"MaassenVanDenBrink A, Reekers M, Bax WA et al (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25\u201330","journal-title":"Circulation"},{"key":"812_CR25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0031-6997(24)01495-9","volume":"53","author":"S Guimar\u00e3es","year":"2001","unstructured":"Guimar\u00e3es S, Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319\u2013356","journal-title":"Pharmacol Rev"},{"key":"812_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0014-2999(74)90150-2","volume":"27","author":"E M\u00fcller-Schweinitzer","year":"1974","unstructured":"M\u00fcller-Schweinitzer E (1974) Studies on the peripheral mode of action of dihydroergotamine in human and canine veins. Eur J Pharmacol 27:231\u2013237","journal-title":"Eur J Pharmacol"},{"key":"812_CR27","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/sj.bjp.0703915","volume":"132","author":"EW Willems","year":"2001","unstructured":"Willems EW, Valdivia LF, Saxena PR et al (2001) The role of several \u03b11- and \u03b12-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol 132:1292\u20131298","journal-title":"Br J Pharmacol"},{"key":"812_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0014-2999(96)00229-4","volume":"305","author":"L Zhou","year":"1996","unstructured":"Zhou L, Vargas HM (1996) Vascular alpha 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur J Pharmacol 305:173\u2013176","journal-title":"Eur J Pharmacol"},{"key":"812_CR29","doi-asserted-by":"crossref","unstructured":"Daly CJ, Deighan C, McGee A, et al (2002) A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 9:85-91","DOI":"10.1152\/physiolgenomics.00065.2001"},{"key":"812_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0014-2999(96)00780-7","volume":"318","author":"K Gavin","year":"1996","unstructured":"Gavin K, Docherty JR (1996) Investigation of the subtype of \u03b12-adrenoceptor mediating pressor responses in the pithed rat. Eur J Pharmacol 318:81\u201387","journal-title":"Eur J Pharmacol"},{"key":"812_CR31","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1111\/bph.12813","volume":"171","author":"H Yoshiki","year":"2014","unstructured":"Yoshiki H, Uwada J, Anisuzzaman AS et al (2014) Pharmacologically distinct phenotypes of \u03b11B -adrenoceptors: variation in binding and functional affinities for antagonists. Br J Pharmacol 171:4890\u20134901","journal-title":"Br J Pharmacol"},{"key":"812_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2010.06.005","volume":"128","author":"S Gupta","year":"2010","unstructured":"Gupta S, Villal\u00f3n CM (2010) The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B\/1D) and CGRP receptors. Pharmacol Ther 128:170\u2013190","journal-title":"Pharmacol Ther"},{"key":"812_CR33","doi-asserted-by":"publisher","first-page":"i2610","DOI":"10.1136\/bmj.i2610","volume":"353","author":"T Kurth","year":"2016","unstructured":"Kurth T, Winter AC, Eliassen AH et al (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610","journal-title":"BMJ"},{"key":"812_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.maturitas.2016.12.008","volume":"97","author":"KM Linstra","year":"2017","unstructured":"Linstra KM, Ibrahimi K, Terwiindt GM et al (2017) Migraine and cardiovascular disease in women. Maturitas 97:28\u201331","journal-title":"Maturitas"},{"key":"812_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.pharmthera.2010.12.001","volume":"129","author":"KY Chan","year":"2011","unstructured":"Chan KY, Vermeersch S, de Hoon J et al (2011) Potential mechanism of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther 129:332\u2013351","journal-title":"Pharmacol Ther"},{"key":"812_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"MaassenVanDenBrink A, Meijer J, Villal\u00f3n CM et al (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779\u2013788","journal-title":"Trends Pharmacol Sci"},{"key":"812_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.2042-7158.1986.tb04590.x","volume":"38","author":"C Korstanje","year":"1986","unstructured":"Korstanje C, Sprenkels R, Doods HN et al (1986) Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in vivo alpha1-, alpha2- and 5-HT2-receptor antagonism and in vitro affinity for alpha1-, alpha2- and 5-HT2-receptor: comparison with ketanserin. J Pharrm Pharmacol 38:374\u2013379","journal-title":"J Pharrm Pharmacol"},{"key":"812_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejphar.2008.10.067","volume":"602","author":"M Buccioni","year":"2009","unstructured":"Buccioni M, Kandhavelu M, Angeli P et al (2009) Identification of \u03b11-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. Eur J Pharmacol 602:388\u2013394","journal-title":"Eur J Pharmacol"},{"key":"812_CR39","first-page":"81","volume":"47","author":"JP Hieble","year":"1996","unstructured":"Hieble JP, Ruffolo RR Jr (1996) Subclassification and nomenclature of alpha 1- and alpha 2-adrenoceptors. Prog Drug Res 47:81\u2013130","journal-title":"Prog Drug Res"},{"key":"812_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/jm980053f","volume":"41","author":"MA Patane","year":"1998","unstructured":"Patane MA, Scott AL, Broten TP et al (1998) 4-Amino-2-4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1dimethylethyl)amino]carbo-nyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314): A potent and selective alpha1b adrenergic receptor antagonist. J Med Chem 41:1205\u20131208","journal-title":"J Med Chem"},{"key":"812_CR41","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1016\/0014-2999(94)00751-R","volume":"272","author":"AS Goetz","year":"1995","unstructured":"Goetz AS, King HK, Ward SD et al (1995) BMY 7378 is a selective antagonist of the D subtype of \u03b11-adrenoceptors. Eur J Pharmacol 272:R5\u2013R6","journal-title":"Eur J Pharmacol"},{"key":"812_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0014-2999(89)90801-7","volume":"168","author":"P Young","year":"1989","unstructured":"Young P, Berge J, Chapman H et al (1989) Novel \u03b12-adrenoceptor antagonist show selectivity for \u03b12A- and \u03b12B-adrenoceptor subtypes. Eur J Pharmacol 168:381\u2013386","journal-title":"Eur J Pharmacol"},{"key":"812_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejphar.2010.06.021","volume":"643","author":"A Sporkova","year":"2010","unstructured":"Sporkova A, P\u00e9rez-Rivera A, Galligan JJ (2010) Interaction between \u03b11- and \u03b12-adrenoceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries. Eur J Pharmacol 643:239\u2013246","journal-title":"Eur J Pharmacol"},{"key":"812_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1476-5381.1990.tb12968.x","volume":"99","author":"AD Michel","year":"1990","unstructured":"Michel AD, Loury DN, Whiting RL (1990) Assessment of imiloxan as a selective \u03b12B-adrenoceptor antagonist. Br J Pharmacol 99:560\u2013564","journal-title":"Br J Pharmacol"},{"key":"812_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0014-2999(94)90573-8","volume":"252","author":"JC Devedjian","year":"1994","unstructured":"Devedjian JC, Esclapez F, Denis-Pouxviel C et al (1994) Further characterization of human \u03b12-adrenoeptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol 252:43\u201349","journal-title":"Eur J Pharmacol"},{"key":"812_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.bjp.0707005","volume":"150","author":"J Sallinen","year":"2007","unstructured":"Sallinen J, H\u00f6glund I, Engstr\u00f6m M et al (2007) Pharmacological characterization and CNS effects of a novel highly selective \u03b12C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391\u2013402","journal-title":"Br J Pharmacol"},{"key":"812_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1476-5381.1994.tb14771.x","volume":"111","author":"MC Michel","year":"1994","unstructured":"Michel MC, Hanft G, Gross G (1994) Functional studies on \u03b11-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol 111:539\u2013546","journal-title":"Br J Pharmacol"},{"key":"812_CR48","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0022-3565(25)24043-5","volume":"271","author":"S Uhl\u00e9n","year":"1994","unstructured":"Uhl\u00e9n S, Porter AC, Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 271:1558\u20131565","journal-title":"J Pharmacol Exp Ther"},{"key":"812_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0306-3623(98)00252-3","volume":"33","author":"GP McCafferty","year":"1999","unstructured":"McCafferty GP, Naselsky DP, Hieble JP (1999) Characterization of postjunctional \u03b1-adrenoceptors in the pithed mouse. Gen Pharmacol 33:99\u2013105","journal-title":"Gen Pharmacol"},{"key":"812_CR50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00210-007-0221-3","volume":"376","author":"T G\u00f6rnemann","year":"2008","unstructured":"G\u00f6rnemann T, J\u00e4hnichen S, Schurad B et al (2008) Pharmacological properties of a wide array of ergolines at functional \u03b11-adrenoceptor subtypes. Naunyn Schmiedeberg's Arch Pharmacol 376:321\u2013330","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-017-0812-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0812-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0812-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:23:55Z","timestamp":1750926235000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-017-0812-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1186\/s10194-017-0812-4","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"type":"print","value":"1129-2369"},{"type":"electronic","value":"1129-2377"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"article-number":"104"}}